NVO · NYSE
Novo Nordisk A/S
$39.00 -0.45 (-1.13%)
Company overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $173B
- Employees
- 77,406
- Headquarters
- Bagsvaerd
- Website
- novonordisk.com
- CEO
- Maziar Mike Doustdar
- Listed
- April 30, 1981
- P/E
- 1.42
- Dividend yield
- 4.00%
Company financials
- Revenue
- $328B
- Gross profit
- $268B
- Operating income
- $148B
- EBITDA
- $182B
- Net income
- $122B
- EPS
- $27.45
- Total assets
- $559B
- Total debt
- $146B
- Gross margin
- 81.85%
- Net margin
- 37.20%
- Earnings yield
- 70.38%
No product segmentation.
Showing FY 2023
NVO
1D
NYSE
O39.39H39.77L39.24C39.43+0.37 (+0.95%)Vol8.56M